Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel.
Glenmark Pharmaceuticals has been charged with conspiring to fix prices for generic drugs, according to a statement released by the US Department of Justice.
Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.
Labrador Diagnostics has dropped its controversial patent complaint against COVID-19 test developer BioMerieux.
Johnson & Johnson has accused a medical supplier of distributing counterfeit surgical tools that are “bacterially contaminated and critically defective”.
The executive director of the Medicines Patent Pool says it should have a role in fighting COVID-19, but it’s up to stakeholders to agree what that will be.
The English Court of Appeal has rejected Neurim’s attempt to block sales of a generic version of its insomnia drug made by Mylan ahead of a patent infringement trial.
Latham & Watkins has added two life sciences-focused litigators, Arlene Chow and Ernest Yakob, to its New York office.
Gilead Sciences has begun a potential takeover of Pionyr Immunotherapeutics after it agreed to pay $275 million for a 49.9% equity stake in the cancer research company.
The UK Supreme Court today has sided with biopharmaceutical company Kymab, allowing its appeal in a suit involving Regeneron and patents covering transgenic mice.